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Cytotoxic T-lymphocyte (CTL) activity plays a central role in control of viral replication and in determining
outcome in cases of human immunodeﬁciency virus type 1 (HIV-1) infection. Incorporation of important CTL
epitope sequences into candidate vaccines is, therefore, vital. Most CTL studies have focused upon small
numbers of adult Caucasoid subjects infected with clade-B virus, whereas the global epidemic is most severe
in sub-Saharan African populations and predominantly involves clade-C infection in both adults and children.
In this study, sensitive enzyme-linked immunospot (elispot) assays have been utilized to identify the dominant
Gag-speciﬁc CTL epitopes targeted by adults and children infected with clade-B or -C virus. Cohorts evaluated
included 44 B-clade-infected Caucasoid American and African American adults and children and 37 C-clade-
infected African adults and children from Durban, South Africa. The results show that 3 out of 46 peptides
spanning p17
Gag and p24
Gag sequences tested contain two-thirds of the dominant Gag-speciﬁc epitopes,
irrespective of the clade, ethnicity, or age group studied. However, there were distinctive differences between the
dominant responses made by Caucasoids and Africans. Dominant responses in Caucasoids were more often
within p17
Gag peptide residues 16 to 30 (38 versus 12%; P < 0.01), while p24
Gag peptide residues 41 to 60
contained the dominant Gag epitope more often in the African subjects tested (39 versus 4%; P < 0.005).
Within this 20-mer p24
Gag, an epitope presented by both B42 and B81 is deﬁned which represents the dominant
Gag response in >30% of the total infected population in Durban. This epitope is closely homologous with
dominant HIV-2 and simian immunodeﬁciency virus Gag-speciﬁc CTL epitopes. The ﬁne focusing of dominant
CTL responses to these few regions of high immunogenicity is of signiﬁcance to vaccine design.
Evidence has accumulated over the past 13 years which
argues that human immunodeﬁciency virus (HIV)-speciﬁc cy-
totoxic T lymphocytes (CTL) are central to the control of
viremia and thus to long-term AIDS-free survival from the
infection (7, 8, 18, 23, 38–40, 45, 49, 51, 64, 68). High levels of
CTL are typically observed in asymptomatic infected adults,
whereas CTL numbers decline in association with progression
to AIDS (38, 64). In acute infection, the appearance of CTL is
temporally linked with the reduction in viremia which occurs
both in HIV and simian immunodeﬁciency virus (SIV) infec-
tion (7, 40, 68). Failure to control viremia, in either primary
infection or chronic infection, may be associated with escape
mutations arising within immunodominant epitopes (8, 18, 23,
39, 49, 50). Chronic HIV-infected adults naive to antiretroviral
therapy also show a strong negative association between CTL
numbers and viral load (47). More recently, experiments using
anti-CD8 monoclonal antibody (MAb) infusions in SIV-in-
fected macaques have demonstrated more directly that plasma
virus levels show strong negative associations with CTL num-
bers, in both acute and chronic infection (30, 53). Macaques
whose CTL response was delayed or abrogated altogether pro-
gressed signiﬁcantly more rapidly to disease and death. To-
gether, these data indicate that HIV-speciﬁc CTL responses
constitute an essential component of an effective HIV vaccine.
Vaccine development urgently needs to target the popula-
tions and the clades of virus most relevant to the worldwide
epidemic. Sub-Saharan Africa is estimated to have borne two-
thirds of the global burden of HIV infection (5). C-clade virus
is the most prevalent clade of HIV infection worldwide (4).
The scale of the clade-C epidemic is illustrated by the antena-
tal prevalence rates in KwaZuluNatal, the most densely pop-
ulated province within South Africa: 10 years ago less than 1%
of antenatal mothers were infected; today the ﬁgure is greater
than 40% (56, 65). The demographic groups most affected are
young (15- to 30-year-old) women (annual incidence of new
infection, 11% [A. Karim, unpublished data]) and infants (in-
cidence of new infection, 10 to 12% [15, 56]). Thus, whereas
published studies have focused upon B-clade-infected Cauca-
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to C-clade-infected African mothers and infants.
These studies were therefore designed to take the initial
steps in identifying the epitopes which dominate the CTL re-
sponse in the ethnic groups and age groups worst hit by the
global epidemic. We focused ﬁrst upon Gag-speciﬁc responses
since Gag-speciﬁc responses have been shown to be associated
with protection in HIV and SIV infection (30, 38, 47, 52, 53).
We used an approach based on enzyme-linked immunospot
assays (elispots [41]) to identify the dominant epitopes tar-
geted in persons who generated Gag-speciﬁc responses. The
main advantage of elispot assays is that the epitope-speciﬁc
CTL response in large numbers of infected persons can be
characterized rapidly and effectively; previous epitope-speciﬁc
studies which have relied upon more labor-intensive methods
have necessarily involved no more than a few subjects. In
addition, the high sensitivity of the elispot assays also facilitates
study of pediatric CTL responses.
Eighty-one children and adults infected with HIV were stud-
ied in order to determine the immunodominant CTL epitopes
presented by HLA class I molecules which are prevalent in a
variety of ethnic groups. The ethnic groups best represented in
these studies were African (62% of the subjects studied) and
Caucasoid (30%) (plus 6% Haitian). We show that the immu-
nodominant Gag-speciﬁc CTL responses are tightly focused on
three highly immunogenic regions which together span 16% of
the total length of p17
Gag and p24
Gag, but which represent
two-thirds of the dominant Gag-speciﬁc CTL responses de-
tected. Although there were no differences observed in the
immunodominant epitopes targeted by infected adults and
children, distinctive patterns of immunodominance were ap-
parent when the Caucasoid subjects were compared with the
Africans studied. These data are relevant to the development
of vaccines designed to develop or boost anti-HIV cellular
immunity in the face of the potential obstacle posed by high
major histocompatibility complex (MHC) diversity.
MATERIALS AND METHODS
Subjects. The 36 children studied attended clinics at the Boston Children’s
Hospital, Boston Medical Center, and Cato Manor Clinic, Durban, South Africa.
All were infected via mother-to-child transmission. The mean age of the children
studied was 7.5 years. The 45 adults studied attended clinics at the Massachusetts
General Hospital, Boston, and Cato Manor Clinic and King Edward VIII Hos-
pital, Durban, South Africa. All of the adults studied except the two hemophil-
iacs were infected via sexual transmission. Of the adults studied in the Boston
cohorts, seven subjects were infected less than 24 months prior to the assay being
performed.
All of the children in the Boston cohorts were receiving antiretroviral therapy,
which included nucleoside and nonnucleoside reverse transcriptase inhibitors but
not protease inhibitors. Five of the 16 adults in the Boston cohort had been
previously treated with a triple therapy regimen consisting of one protease
inhibitor and two reverse transcriptase inhibitors, but at the time of evaluation
none of the 16 adults were receiving antiretroviral therapy. All of the children
and adults in the Durban cohorts were antiretroviral therapy-naive.
Peptides. Lymphocytes from the Boston cohorts of adults and children studied
were tested for recognition of a panel of 46 overlapping peptides, 15 to 20 amino
acids in length, spanning p17
Gag and p24
Gag B-clade SF2 sequence (all provided
by the National Institute for Biological Standards and Control Centralized Fa-
cility for AIDS Reagents, supported by European Union Program EVA and the
United Kingdom Medical Research Council, except for 12 overlapping p17
Gag
peptides, which were synthesized commercially [Research Genetics, Huntsville,
Ala.]). Lymphocytes from the Durban cohort of adults and children studied were
tested for recognition of a similar panel of 46 overlapping C-clade p17
Gag and
p24
Gag peptides, 15 to 20 amino acids in length. These C-clade sequences were
designed to represent a consensus sequence, derived from the published se-
quences available at the HIV website (www.hiv-lanl.gov). The peptides in both B-
and C-clade panels overlapped by 10 to 11 amino acids, and thus there were no
regions within p17
Gag and p24
Gag which were not fully represented by these
peptides. The rationale for using B-clade-based sequences for study of the
Boston cohorts and C-clade-based sequences for the Durban cohorts was that
these are the respective clades of virus overwhelmingly dominant in HIV-in-
fected persons in North America and Southern Africa, respectively (4).
Elispot assays. Fresh peripheral blood mononuclear cells (PBMCs) were sep-
arated from whole blood by Ficoll-Hypaque (Sigma, St. Louis, Mo.) density
gradient centrifugation and were plated out in 96-well polyvinylidene plates
(Millipore, Bedford, Mass.) which had been precoated with 0.5-mg/ml anti-
gamma interferon (IFN-g) MAb 1-DIK (Mabtech, Stockholm, Sweden). The
peptides were added in a volume of 20 ml and then PBMCs were added at 50,000
cells per well in a volume of 180 ml. The ﬁnal concentration of the peptides was
10 mM. The plates were incubated overnight at 37°C in 5% CO2 and were washed
with phosphate-buffered saline before the addition of the second, biotinylated
anti-IFN-g MAb, 7-B6-1 biotin (Mabtech), at 0.5 mg/ml and were incubated at
room temperature for 100 min. Following washing, streptavidin-conjugated al-
kaline phosphatase (Mabtech) was added at room temperature for 40 min.
Individual cytokine-producing cells were detected as dark spots after a 20-min
reaction with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium
by using an alkaline phosphatase-conjugate substrate (Bio-Rad, Richmond, Cal-
if.). The number of speciﬁc T cells was calculated by subtracting the negative
control values, unless the background was above 40 spot-forming cells (sfcs) per
one million PBMCs (two immunospots/well at 50,000 PBMCs/well), in which
case the assay was repeated. Signiﬁcant Gag-speciﬁc responses were deﬁned as
responses at a frequency of 100 per one million PBMCs or higher (represented
by ﬁve immunospots/well or more, at 50,000 PBMCs/well).
In all cases, positive responses were additionally veriﬁed by at least one of ﬁve
methods: by demonstration of recognition of the same overlapping peptide in
PBMCs from more than one time point; by recognition in repeat elispot assays
of shorter 8- to 11-mer peptides contained within longer peptides that were
recognized; by demonstration in repeat elispot assays of the same peptide-
speciﬁc response in CD8
1 positively sorted lymphocyte populations or CD4
1-
depleted lymphocyte populations, but not in CD8
1-depleted or CD4 positively
sorted lymphocyte populations; by staining of cells with the appropriate peptide-
MHC tetramer; or by chromium release assays following the generation of CTL
clones by using MHC class I-matched target cells. False-positive responses due to
peptide contamination were further excluded by use of the same peptides in
elispot assays using negative control PBMCs from nonresponsive subjects.
Immunodominance of the CTL response. The immunodominant response was
deﬁned as the strongest response detected in the elispot assay. If more than 50
spots were counted in a well, the frequency was determined to be .1,000 per one
million PBMCs for an input number of 50,000 PBMCs/well. In some cases, where
more than one response was present at .1,000 per one million PBMCs, the
dominance of the response was determined by repeat assays by using lower input
numbers of PBMCs/well, down to 4,000 PBMCs/well. Where repeat assays could
not be undertaken because of lack of cell availability, the responses present at
.1,000 per one million PBMCs were considered codominant.
Cell sorting. Sorting of cells into CD4
1 and CD8
1 T-cell-enriched and -de-
pleted populations was done by using magnetic microbeads (Miltenyi Biotech).
Greater than 99% purity was achieved in the positively sorted populations.
MHC-tetramer staining of lymphocytes. Staining of lymphocytes was carried
out by using the A*0201-SLYNTVATL tetrameric complex and the B42-
TPQDLNTML complex, as appropriate. The phycoerythrin-labelled complexes
were prepared as previously described (2). PBMCs or effector cells (500,000)
were incubated for 15 min at 37°C with 0.5 mg of the appropriate tetramer and
then for an additional 10 min with saturating amounts of PerCP-conjugated
anti-CD8 monoclonal antibody and ﬂuorescein isothiocyanate-conjugated anti-
CD4 MAb (Becton Dickinson). Stained samples were analyzed on a FACSCali-
bur ﬂow cytometer using CellQuest software. Control samples for the tetramer
staining were PBMCs from HLA-mismatched HIV-infected persons. Quadrant
boundaries for tetramer staining were established by exclusion of .99.97% of
control CD8
1 T cells.
Generation of CTL clones and precursor frequency assays. CTL clones were
generated by using methods previously described (63). In brief, PBMCs were
plated out in 96-well plates at limiting dilution (100 to 10 cells/well) and were
cultured with irradiated allogeneic feeder PBMCs at 50,000 cells/well in a ﬁnal
volume per well of 200 ml of R10 medium (RPMI 1640 medium [Sigma]), 10%
fetal calf serum (Sigma), and 10 mM HEPES buffer (M-2-hydroxyethylpipera-
zine-N-2-ethanesulfonic acid; Sigma) with antibiotics (2 mM L-glutamine and 50
U of penicillin-streptomycin per ml). The anti-CD3 MAb, 12F6, was added at
100 mg/ml. On day 5 and once weekly thereafter, the medium was changed with
R10 medium containing 50 U of recombinant interleukin 2. Wells were screened
for speciﬁc recognition of HLA-matched, peptide-pulsed,
51Cr (New England
Nuclear, North Billerica, Mass.)-labelled Epstein-Barr virus-transformed B-lym-
phoblastoid cell line (BCL) target cells after 21 to 28 days in culture. Wells
showing high speciﬁc recognition of the relevant peptide were then transferred
to 24-well plates and were restimulated as above, except 10
6 feeders were added
to each well and recombinant interleukin 2 was added on day 0. Expanded wells
were then retested for lytic activity from day 14 of culture onwards and were
maintained in culture by monthly restimulations as described.
Precursor frequency assays were set up in the same way, except that dilutions
of PBMCs from 16,000 to 100 cells per well were plated out in 24 replicate wells.
Chromium release assays (62) using HLA-matched BCL targets were performed
after 14 to 21 days of culture.
Chromium release assays. BCL target cells were labelled with chromium-51 by
incubation of pelleted BCL with 50 mCi of Na2CrO4 (New England Nuclear) for
1 h at 37°C in 5% CO2. Targets were washed thrice and were then incubated with
5680 GOULDER ET AL. J. VIROL.peptide dilutions (in the peptide titration assays) for a further 90 min prior to
addition of effectors. The supernatants were harvested following 4 to6ho f
further incubation at 37°C in 5% CO2 (62).
HLA typing. HLA typing was performed by sequence-speciﬁc primer PCR
(SSP-PCR) (11).
RESULTS
Dominant Gag-speciﬁc CTL responses in B-clade-infected
persons. The method by which the dominant Gag-speciﬁc re-
sponse was determined by using the elispot assays described
and the methods by which the CD8 T-cell dependence of these
responses were conﬁrmed are illustrated for one infected indi-
vidual in Fig. 1. Three 15-mer peptides out of 24 overlapping
p17
Gag peptides stimulated responses (Fig. 1A), the best re-
sponse of which was to peptide p17.8 (GSEELRSLYNTVA
TL, residues 71 to 85). Following positive and negative cell
sorting using CD4- and CD8-conjugated magnetic microbeads,
respectively, the response to the 15-mer GSEELRSLYNT
VATL was retested, and IFN-g-producing cells were found
only within CD4 T-cell-depleted populations and positively
sorted CD8 T-cell populations (Fig. 1B). The precursor fre-
quency assay, using A*0201-matched target cells pulsed with
the optimal epitope peptide SLYNTVATL (31, 59), showed
speciﬁc recognition of this peptide at a frequency of 3,354 per
one million PBMCs (Fig. 1C). This was comparable with the
level of tetramer staining of PBMCs, which was 1.02% or
10,200 per one million PBMCs (Fig. 1D).
The HLA types and dominant Gag-speciﬁc responses in the
pediatric and adult Boston cohorts studied (n 5 44) are shown
in Table 1. The ethnic groups represented in the Boston co-
horts were African (41%), Hispanic (3%), and Caucasoid
(57%), all presumed to be infected with B-clade virus (4). All
16 adults tested and all but four of the children tested (28 of 32
[88%]) made Gag-speciﬁc responses at frequencies of .100
per one million PBMCs. Irrespective of the HLA types of the
persons in the Boston cohorts studied, a minority of the 46 15-
to 20-mer overlapping clade-B peptides spanning p17
Gag and
p24
Gag were disproportionately targeted by the dominant Gag-
speciﬁc CTL. Overall, three peptides, WEKIRLRPGGKKKY
KLK (p17 residues 16 to 30), GSEELRSLYNTVATL (p17
Gag
residues 71 to 85), and SALSEGATPQDLNTMLNTVG
(p24
Gag residues 41 to 60), together representing 15% of the
length of sequence spanned by the 46 overlapping peptides,
contained the dominant Gag-speciﬁc epitope in 31 of 44
(70%) persons tested who showed Gag-speciﬁc responses
(Table 1).
Dominant Gag-speciﬁc CTL responses in C-clade-infected
persons. The HLA types and dominant Gag-speciﬁc responses
in the pediatric and adult Durban cohorts studied (n 5 37) are
shown in Table 2. The ethnic group studied within the Durban
was uniformly African, subjects coming from the Zulu and
Xhosa tribal groups. Thirty-seven of 44 persons tested (84%)
showed Gag-speciﬁc responses at a frequency of .100 per one
million PBMCs. Once again, a minority of the 46 15- to 20-mer
C-clade-based overlapping peptides spanning p17
Gag and
p24
Gag were disproportionately targeted by the dominant Gag-
speciﬁc CTL in the 37 persons studied who showed responses
FIG. 1. (A) Elispot assay testing recognition by PBMCs from donor 161j (HLA class I type; HLA-A*0201/3 B7/60 Cw3/7) of the panel of 24 overlapping p17
Gag
peptides. A sample of 36,000 PBMCs per well was used (i.e., one spot represented 28 spot-forming cells [SFC]). More than 45 spots were present in the well containing
peptide p17.8 (sequence GSEELRSLYNTVATL); thus the frequency of SFC speciﬁc for this peptide was .1,250 SFC per one million. (B) Elispot assay in panel A
repeated using sorted cells and testing recognition only of peptide p17.8. (C) Precursor frequency assay using PBMCs from donor 161j, tested against the optimal
HLA-A*0201-restricted epitope, SLYNTVATL, using A*0201-matched target cells. (D) Staining of PBMCs from donor 161j with the A*0201-SLYNTVATL
MHC-peptide tetrameric complex, showing 1% of PBMCs staining with the tetramer.
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Overall, three peptides, representing 16% of the length of
sequence spanned by the 46 overlapping peptides, contained
the dominant Gag-speciﬁc epitope in 23 of 37 (63%) persons
tested. These C-clade peptides, RLRPGGKKHYMIKHLVW
(p17
Gag residues 20 to 36), ELRSLYNTVATLYCV (p17
Gag
residues 74 to 88), and SALSEGATPQDLNTMLNTVG
(p24
Gag residues 41 to 60), either closely or exactly overlap the
three most immunogenic B-clade peptides identiﬁed. Two ad-
ditional p24
Gag peptides, FRDYVDRFFKTLRAEQA (resi-
dues 161 to 177) and SILDIKQGKEPFRDY (residues 149 to
164), together with the three listed above, account for the dom-
inant or codominant Gag-speciﬁc response in 32 of 37 (86%)
of the clade-C-infected subjects studied.
TABLE 1. Gag-speciﬁc CTL responses in Boston cohorts studied
Best-recognized
peptide Subject HLA class I type Racial group CTL (per one
million PBMCs)
Deﬁned dominant epitope
[HLA restriction]
a
p17.2A 014-TCH A*0201/3 B35/44 Cw1/4 African American Caucasoid 600 RLRPGGKKK [A3]
019-TCH A3/*3001 B51/60 CW15/16 Caucasoid 723 KIRLRPGGK [A3]
027-TCH A1/*0201 B18/57 Cw6/7 Caucasoid 472 WEKIRLRPGGKKKYK [ND
b]
048-TCH A1/*0201 B27/37 Cw2/6 Caucasoid 780 IRLRPGGKK [B27]
049-TCH A1/24 B27/37 Cw1/6 Caucasoid 170 IRLRPGGKK [B27]
004-BMC A3/*3001 B7/35 Cw4/7 Haitian 273 KIRLRPGGK [A3]
011-BMC A24/29 B7/45 Cw6/7 African American 170 RLRPGGKKKYK [ND]
96/00600 A3/11 B44/62 Cw3/5 Caucasoid 225 WEKIRLRPGGKKKYK [ND]
96/01114 A2/3 B35/- Cw4/- Caucasoid .1,000 RLRPGGKKK [A3]
85/00003 A*0201/3 B7/51 Cw7/- Caucasoid .1,000 RLRPGGKKK [A3]
JC A*0201/3 B35/55 Cw-/- Caucasoid 880 RLRPGGKKK [A3]
GV A*0201/3 B8/62 Cw7/10 Caucasoid 280 RLRPGGKKK [A3]
TD A3/68 B35/44 Cw4/7 Caucasoid 1,280 RLRPGGKKK [A3]
p17.4A 042-TCH A3/33 B35/53 Cw4/- African American .1,000 WASRELERF [ND]
p17.8 001-UNC A*0201/74 B7/35 Cw7/16 African American 2,800 SLYNTVATL [A*0201]
004-TCH A*0202/29 B7/44 Cw7/16 Caucasoid Hispanic 1,400 SLYNTVATL [A*0202]
032-TCH A*0201/23 B44/61 Cw2/4 Caucasoid 160 SLYNTVATL [A*0201]
034-TCH A*0201/68 B35/44 Cw4/7 Caucasoid 120 SLYNTVATL [A*0201]
036-TCH A*0201/68 B18/51 Cw5/16 Haitian 213 SLYNTVATL [A*0201]
040-TCH A*0201/34 B7/52 Cw7/16 Haitian 400 SLYNTVATL [A*0201]
007-BMC A*0201/23 B14/45 Cw6/8 African American 520 SLYNTVATL [A*0201]
010-161j A*0201/3 B7/60 Cw3/7 Caucasoid .2,000 SLYNTVATL [A*0201]
9354 A*0201/3 B7/35 Cw4/7 Caucasoid 5,600 SLYNTVATL [A*0201]
013-661 A1/*0201 B44/52 Cw-/- Caucasoid 920 SLYNTVATL [A*0201]
85/00003 A*0201/3 B7/51 Cw7/- Caucasoid .1,000 SLYNTVATL [A*0201]
p17.8A 013-199 A*0201/*3002 B44/51 Cw-/- Caucasoid 5,650 RSLYNTVATLY [A*3002]
p17.9A 028-BMC A1/*0201 B8/63 Cw7/- Caucasoid .1,000 DVKDTKEAL [ND]
045-TCH A23/68 B45/72 Cw2/16 Haitian 133 RIDVKDTKEAL [ND]
p24.2 033-BMC A34/68 B57/71 Cw3/7 Haitian 500 VQHAISPRTLNAWV [ND]
p24.3 GS A*0201/30 B44/57 Cw-/- Caucasoid 770 KAFSPEVIPMF [B57]
p24.5 015-TCH A*3002/68 B14/*5802 Cw6/8 African American 462 GATPQDLNTMLNTV [ND]
016-TCH A*3001/- B42/- Cw17/- African American 507 TPQDLNTML [B42]
044-TCH A*0201/30 B42/52 Cw16/17 African American 1,450 TPQDLNTML [B42]
009-BMC A*0201/*3002 B14/27 Cw1/8 African American 360 TPQDLNTML [B14/Cw8]
021-BMC A3/*3001 B42/- Cw17/- African American .1,000 TPQDLNTML [B42]
026-BMC A3/- B42/*5703 Cw7/17 Hispanic 2,460 TPQDLNTML [B42]
032-BMC A1/80 B42/45 Cw16/17 African American 1,810 TPQDLNTML [B42]
94/00181 A11/24 B14/44 Cw8/16 Caucasoid .1,000 TPQDLNTML [ND]
p24.13 029-TCH A*0201/32 B7/8 Cw7/15 Caucasoid 433 EIYKRWII [B8]
p24.14 023-TCH A23/26 B62/72 Cw2/3 African American 660 GLNKIVRMY [B62]
043-TCH ND African American 1,500 KRWILGLNKIVRMY [ND]
p24.17 KM A3/- B14/60 Cw3/8 Caucasoid 1,600 DRFYKTLRA [B14]
JFM A*0201/68 B14/44 Cw5/8 Caucasoid 120 DRFYKTLRA [B14]
p24.22 KS A3/- B7/- Cw7/- Caucasoid 1,020 GPSHKARVL [B7]
DK A*0201/11 B18/44 Cw-/- Caucasoid 1,300 ACQGVGGPGHK [A11]
a In each case the deﬁned epitopes shown represent the HLA restriction, and epitope optimization was determined for each subject. Optimized epitopes described
elsewhere (for example, WASRELERF as a B35-restricted epitope [10]) are not shown unless the response was demonstrated in the subjects studied.
b ND, not determined.
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Gag regions containing the dominant CTL responses which
were detected in the Caucasoid subjects studied (n 5 24) were
compared with those targeted by dominant responses in the
non-Caucasoids studied (n 5 57), all but two of whom were
ethnic Africans (Fig. 2). The region predominantly targeted by
Caucasoids was in p17 (peptide p17 residues 16 to 30), which
contained the immunodominant epitope in 38% of persons
studied. In comparison, this region only accounted for 12% of
the dominant responses in the non-Caucasoids studied (x
2 5
7.0; P , 0.01, Fisher’s exact test). In contrast, one peptide in
p24
Gag (residues 41 to 60) accounted for 39% of dominant Gag
responses in the Africans studied, compared with 4% in Cau-
casoids studied (x
2 5 10.3; P , 0.005, chi-square test). Com-
parisons of the epitopes targeted by pediatric and adult sub-
jects showed no signiﬁcant differences (data not shown).
TABLE 2. Gag-speciﬁc CTL responses in the Durban cohorts studied
Best-recognized
peptide Subject
a HLA class I type CTL (per one
million PBMCs) Deﬁned dominant epitope [HLA restriction]
p17c.4 RCC-001 A3/23 B49/5802 Cw6/- 1,000 RLRPGGKKK [A3]
RCC-002 A*3001/66 B42/81 Cw4/17 .1,000 RLRPGGKKHYMIKHLVW [ND
b]
338-M A2/69 B7/42 Cw7/17 .1,000 RLRPGGKKHYMIKHLVW [ND]
KEH04-M A30/- B42/72 Cw2/17 354 RLRPGGKKHYMIKHLVW [ND]
p17c.7 RCC-006 A6801/- B62/71 Cw-/- 600 LVWASRELERFALNPGL [ND]
RCC-007 ND 1,000 LVWASRELERFALNPGL [ND]
p17c.11 338-M A2/69 B7/42 Cw7/17 .1,000 IIKQLQPALQTGTEEL [ND]
p17c.13 338-M A2/69 B7/42 Cw7/17 .1,000 SLYNTVATL [A2]
325-M A3/30 B*5802/72 Cw2/6 .1,000 ELRSLYNTVATLYCV [ND]
200-M ND 1,500 ELRSLYNTVATLYCV [ND]
KEH18-M A*6802/- B44/*5802 Cw4/6 320 ELRSLYNTVATLYCV [ND]
p24c.3 994-M A3/74 B57/62 Cw04/- 760 NAWVKVIEEKAFSPEVIPF [ND]
p24.5 1020-C5Y A2/*3002 B14/*5802 Cw6/8 640 TPQDLNTML [ND]
1023-C6W A24/30 B8/72 Cw2/7 540 TPQDLNTML [ND]
021-M A1/34 B72/81 Cw2/18 .1,000 SALSEGATPQDLNTMLNTVG [ND]
023-M A29/3002 B7/42 Cw7/17 .1,000 SALSEGATPQDLNTMLNTVG [ND]
252-M A29/*6802 B18/*5802 Cw5/6 .1,000 SALSEGATPQDLNTMLNTVG [ND]
270-M A23/*6802 B41/71 Cw3/17 .1,000 SALSEGATPQDLNTMLNTVG [ND]
272-M A30/34 B*5802/81 Cw6/18 .1,000 SALSEGATPQDLNTMLNTVG [ND]
298-M A1/*6801 B*5802/81 Cw6/18 .1,500 SALSEGATPQDLNTMLNTVG [ND]
982-M ND .1,000 TPQDLNTML [ND]
987-M A2/*3002 B*5801/81 Cw04/- .1,000 TPQDLNTML [ND]
991-M A1/*3002 B8/81 Cw7/18 980 TPQDLNTML [ND]
1023-M A2/24 B8/*5802 Cw6/7 .1,000 SALSEGATPQDLNTMLNTVG [ND]
1031-M ND .1,000 TPQDLNTML [ND]
KEH01-M A30/68 B14/42 Cw8/17 380 SALSEGATPQDLNTMLNTVG [ND]
KEH02-M A30/- B42/72 Cw2/17 900 SALSEGATPQDLNTMLNTVG [ND]
KEH19-M A*3002/66 B42/*5802 Cw6/17 920 TPQDLNTML [B42]
p24c.16 RC-005 ND 520 NPPIPVDIYKRWII [ND]
973-M A1/3 B8/- Cw7/- 1,860 DIYKRWII [B8]
p24c.17 1020-M A2/- B*5802/62 Cw4/6 900 GLNKIVRMY [ND]
p24c.20 RCC-007 ND 1,000 SILDIKQGPKEPFRDY [ND]
109-M A2/23 B72/- Cw2/- 420 SILDIKQGPKEPFRDY [ND]
188-M A2/*6801 B18/*5802 Cw5/6 720 SILDIKQGPKEPFRDY [ND]
260-M ND 173 SILDIKQGPKEPFRDY [ND]
p24c.22 RCC-004 A23/69 B-/- Cw3/18 .1,000 FRDYVDRFFKTLRAEQA [ND]
022-M A*3001/*3002 B42/45 Cw3/17 380 FRDYVDRFFKTLRAEQA [ND]
270-M A23/*6802 B41/71 Cw3/17 .1,000 FRDYVDRFFKTLRAEQA [ND]
971-M A26/68 B8/71 Cw3/7 1,080 FRDYVDRFFKTLRAEQA [ND]
1011-M A*6802/74 B71/- Cw3/4 840 FRDYVDRFFKTLRAEQA [ND]
p24c.24 RCC-004 A23/69 B-/- Cw3/18 .1,000 QATQDVKNWMTDTLLV [ND]
p24c.25 RC-007 ND 520 WMTDTLLVQNANPDCKTI [ND]
p24c.28 KEH14-M A3/33 B71/72 Cw-/- 340 EEMMTACQGVGGPSHKARVL [ND]
a Subjects coded by a number followed by “M” represent adults in the cohort. All subjects were of the African racial group.
b ND, not determined.
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Gag CTL re-
sponse. Having identiﬁed a single peptide, SALSEGATPQD
LNTMLNTVG (SG20) (p24
Gag residues 41 to 60), out of the
46 tested which contained the dominant Gag epitope in 39% of
55 ethnic Africans studied, we proceeded to deﬁne precisely
the optimal epitopes which were targeted. The optimal epitope
identiﬁed in each of the subjects with HLA-B42 which was
characterized was the peptide TPQDLNTML (TL9) (p24
Gag
FIG. 2. Frequency with which each Gag peptide tested contained the dominant CTL response in 81 subjects studied.
FIG. 3. (A) Optimization of the HLA-B42-restricted epitope, TPQDLNTML (TL9). Effectors shown from donor 016-TCH (HLA-A*3001/- B42/- Cw17/-) against
HLA-B42-matched target cells. (B) Staining of PBMCs from 016-TCH with the B42-TL9 MHC-peptide complex, showing 4.19% of CD8
1 T cells staining with the
tetramer. (C) Recognition of TL9-pulsed target cells by 016-TCH clones (as in panel A): target cells included B42-matched targets (square symbols) (autologous targets
are represented by closed squares); HLA-B81-positive, HLA-B42-negative targets (open circles); and HLA-B7-positive, HLA-B42-negative targets (closed circles). (D)
Optimization of the HLA-B14-Cw*0802-restricted epitope TPQDLNTML by elispot assay of PBMCs from donor 009-BMC (A*0201/*3002 B14/27 Cw1/8). HLA
restriction of the response was previously determined by precursor frequency assay by using targets matched through B14 and Cw8 (data not shown).
5684 GOULDER ET AL. J. VIROL.residues 48 to 56 [Fig. 3A and B]). This B42-restricted epitope
was also recognized by B42-positive effectors when presented
by B81-positive target cells (Fig. 3C), reﬂecting the very close
sequence similarity between HLA-B42 and -B81 (6, 61). The
same peptide TL9 is thus almost certainly also an optimal
HLA-B81-restricted epitope (58), although this has not been
deﬁnitively established; however, previous studies have dem-
onstrated that an HLA-B81-restricted epitope exists within the
same 20-mer SG20 (17).
In addition to the B42- and B81-restricted TL9-speciﬁc re-
sponses, which accounted for the dominant CTL responses in
14 of 22 of the HLA-typed subjects targeting the SG20, 5 of 22
of these subjects expressed HLA-B14 and HLA-Cw*0802,
which are in tight linkage disequilibrium (14) and are almost
invariably coexpressed. Although there is a described HLA-
Cw*0802-restricted epitope in SG20 (10), in the subjects stud-
ied here with B14-Cw*0802 whose SG20 response was charac-
terized, the optimal epitope again proved to be TL9 (Fig. 3D),
with no recognition of the described epitope DLNTMLNTV
(10). The HLA restriction of this response was conﬁrmed as
HLA-B14 and HLA-Cw*0802 (data not shown). Distinction
between B14 and Cw8 as the restriction element is compli-
cated by the linkage disequilibrium, but on purely theoret-
ical grounds this epitope would precisely ﬁt the Cw8 peptide
binding motif (Pro, Val, or Leu at position 2, Val or Leu at
position 9) and would not ﬁt the B14 motif (Arg at position 2,
Phe or Tyr at position 3, and Ala or Val at position 9) (52). In
the three remaining HLA-typed subjects who targeted SG20 as
their dominant Gag-speciﬁc CTL response but who did not
have either HLA-B42, HLA-B81, or HLA-B14-Cw8, these re-
sponses have yet to be precisely deﬁned.
The signiﬁcance of the TL9 epitope as an important com-
ponent of the anti-HIV CTL response generated by infected
Zulu and Xhosa in South Africa is that either or both HLA-
B42 and -B81 are expressed in 40 to 45% of infected persons
(M. G. Hammond and P. J. R. Goulder, unpublished data) and
that in 14 of 18 (78%) persons studied who have B42 and/or
B81, this is the dominant Gag-speciﬁc epitope targeted. Thus,
approximately 30% of all Africans expressing HLA class I
molecules in similar frequencies to the subjects studied here in
Durban would be expected to use TL9 as the dominant Gag-
speciﬁc CTL epitope.
Fine speciﬁcity of the immunodominant p17
Gag CTL re-
sponses. Two regions within p17
Gag (p17
Gag residues 16 to 34
and 71 to 88) were predominantly targeted (Fig. 2). The ﬁrst,
represented in the B-clade panel of peptides by the 15-mer
WEKIRLRPGGKKKYK (WK15) (residues 16 to 30), as
stated above, contained signiﬁcantly more dominant epitopes
in the Caucasoids than the non-Caucasoids tested by using the
appropriate B- or C-clade peptides. Of the 10 HLA-typed
Caucasoids whose dominant Gag response was targeted at this
region, seven have HLA-A3. In all of these, the optimal
epitopes were either the previously deﬁned sequences (10, 22),
RLRPGGKKK (in six of seven subjects) or KIRLRPGGK (in
one of seven subjects). Although several epitopes restricted by
HLA alleles other than HLA-A3 are clustered within this re-
gion, such as IRLRPGGKK by HLA-B27 (10), the speciﬁc
focusing of dominant CTL responses in the region of peptide
WK15 in this study is largely explained by the high phenotypic
frequency of HLA-A3 in Caucasoids (20 to 25%) compared to
the frequency in Africans (5 to 10%) (14; M. G. Hammond and
P. J. R. Goulder, unpublished data).
The second region of major immunogenicity identiﬁed in
p17
Gag is represented by the 15-mer ELRSLYNTVATLYCV
(EV15) (residues 74 to 78). Thirteen of ﬁfteen subjects target-
ing this region expressed HLA-A2, and the majority of these
responses are accounted for by the immunodominant HLA-
A*0201-restricted epitope, SLYNTVATL (residues 77 to 85)
(9, 22, 24). This region tended not to feature as prominently in
the Gag-speciﬁc CTL responses of the African subjects studied
(x
2 5 1.50; P . 0.25, Fisher’s exact test), especially in Zulu
subjects studied, where the frequency of the A*0201 subtype
of A2 is very low (;1% of the population) (25). Approxi-
mately 45% of the Caucasoid population studied in Boston
express HLA-A*0201 (14). However, this region also con-
tains the undescribed A*3002-restricted epitope, RSLYNTV
ATLY (P. J. R. Goulder, Y. Tang, M. Bunce, E. S. Rosenberg,
and B. D. Walker, unpublished data). Since HLA-A*3002 is
present at high frequency (25% [M. G. Hammond and P. J. R.
Goulder, unpublished data]) in African populations and low
frequency (,4% [14]) in Caucasoid populations, this region of
p17
Gag is likely to feature strongly in the CTL responses of
both groups.
DISCUSSION
These studies show that, irrespective of a wide diversity in
HLA class I expression between the subjects investigated,
dominant C- and B-clade Gag-speciﬁc CTL responses are fo-
cused upon a small number of highly immunogenic regions.
However, characteristic differences in epitope speciﬁcity were
evident when the different ethnic groups studied were com-
pared. The regions of Gag which contained the dominant
epitope in the majority (64%) of the 24 Caucasoids studied
were in p17
Gag. These regions include epitopes restricted by
HLA-A*0201 and -A3, two alleles occurring frequently in Cau-
casoids. The region of Gag most commonly (39%) containing
the dominant epitope in the 55 ethnic Africans studied was in
p24
Gag. The immunogenicity of this p24
Gag peptide principally
reﬂects the dominant CTL responses made through HLA-B42
and -B81, alleles almost exclusively found in Africans (14).
Finally, the major Gag responses seen in infected adults (n 5
45) did not differ signiﬁcantly from those which were observed
in the infected children studied (n 5 36).
This is by far the largest epitope-speciﬁc study of CTL ac-
tivity to have been undertaken, in which 81 adults and children
were evaluated. The phenomenon of epitopes clustering into
regions of high immunogenicity within proteins is not new (10,
16, 47), but the extent of epitope clustering that evidently exists
from the data described above was not known. Prior to the
advent of elispot assays, epitope-speciﬁc CTL studies were
labor intensive and were necessarily only carried out on very
small numbers of persons at a time. Since only novel epitopes
will be published, a database understates the true degree of
epitope clustering.
These results are potentially of signiﬁcance if CTL epitope
sequences are to be incorporated into candidate vaccines. A
theoretical problem in the approach using CTL epitope se-
quences within polyepitope vaccines would be that individual
vaccines would need to be tailored to the HLA type of each
individual vaccinee. However, if the dominant CTL epitopes
are clustered within very small regions of viral proteins irre-
spective of the HLA type of the potential vaccinee, the same
vaccine may be given to all persons and effective CTL re-
sponses will be induced. Although a proportion of the subjects
studied did show strong responses to epitopes outside the
highly immunogenic regions noted, the degree of immuno-
dominant epitope clustering observed in the majority of sub-
jects is striking. However, these data taken in isolation do not
demonstrate that these particular CTL responses are protec-
tive or beneﬁcial in the control of HIV replication. In fact,
study of acutely infected subjects shows that epitopes targeted
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chronic infection (P. J. R. Goulder, M. A. Altfeld, E. S. Rosen-
berg, Y. Tang, B. Eldridge, B. D. Walker, and C. Brander,
unpublished data). Further investigation of the effectiveness of
the CTL responses that are detectable in chronic infection is
warranted.
The advantage of an approach using polyepitope vaccines,
rather than full-length gene products, to induce stronger CTL
responses has not been deﬁnitively established. However, an
enormous increase in peptide-MHC class I formation resulting
from minigene products has been demonstrated (5, 69). The
subdominance of certain epitopes may partly reﬂect inefﬁcient
processing (67). Polyepitope vaccination in mice has recently
been utilized to induce CTL responses which protect against
virus challenge (57), and, more recently, strong CTL SIV-
speciﬁc responses have been demonstrated in macaques fol-
lowing polyepitope vaccination (26).
A second, more theoretical, advantage of a polyepitope vac-
cine approach would be that differences clearly exist between
CTL (19, 27, 29, 33, 34, 70), such that subdominant CTL
responses may in some cases be more effective in controlling
viremia than dominant responses (19). Simple use of full-
length gene products to induce CTL would not allow the ﬂex-
ibility available in a polyepitope vaccine to exclude immuno-
genic regions which might induce dominant but ineffective
CTL responses. Although many studies have shown associa-
tions of particular HLA class I molecules with differences in
speed of progression to disease in HIV and other infections
(12, 21, 28, 36, 37), the mechanism accounting for these dif-
ferences (which presumably operates through the HLA class
I-restricted CTL activity) has not been elucidated.
The speciﬁcity of the HIV-speciﬁc CTL responses in in-
fected Africans is clearly fundamental to understanding which
epitopes may be important in controlling viremia in the pop-
ulations worst hit by the global epidemic. It is somewhat sur-
prising to discover from the data described here that as much
as one-third of infected Africans target their immunodominant
Gag-speciﬁc CTL response to a single previously undescribed
epitope peptide, whether presented by HLA-B42, -B81 or
-Cw*0802. Strong HLA-B53-restricted CTL responses have
been described (20) towards the exact HIV type 2 homologue
of TL9 (TPYDINQML) and, notably, much of what has been
learned from CTL responses in SIV-infected macaques has
come from study of the single Mamu-A*01-restricted epitope
CTPYDINQM (CM9) (1), which is almost exactly homologous
in sequence to TL9. If the B42- and B81-restricted TL9 re-
sponse is analogous to the Mamu-A*01 CM9 response, then
this TL9 epitope can be expected to play a vital part in control
of HIV in infected Africans (13, 54).
The subjects studied represent an extremely heterogeneous
group, not only with regard to the ethnicity and age of the
persons studied, but also with regard to the clade of virus
responsible for infection and the use of antiretroviral therapy.
In terms of the effect of antiretroviral therapy on the hierarchy
of HIV-speciﬁc CTL responses detectable, the detailed studies
that have been carried out indicate that the magnitude of each
speciﬁcity is diminished, but that the responses persist and the
hierarchy remains the same even years after effective highly
active antiretroviral therapy (34).
The effect of the clade of virus on epitopes targeted may be
gauged by comparing the responses detected in B-clade-in-
fected African Americans and C-clade-infected African Zulu
and Xhosa from KwaZuluNatal. In both groups, the immu-
nodominance of the HLA-B42-restricted TL9-speciﬁc re-
sponse is striking. Although the clade of virus causing infection
was not determined in the speciﬁc African subjects in KwaZu-
luNatal studied, 84 of 90 (93%) infected persons in KwaZulu-
Natal for whom the clade of infecting virus has recently been
determined were infected with clade-C virus (46, 60; D. York,
unpublished data). A measure of the level of variability of the
respective B- and C-clade Gag proteins (Fig. 4) shows that a
similar degree of sequence variation exists in these proteins in
B- and C-clade-infected persons. The data in Fig. 4, however,
do not distinguish between conservative and nonconservative
sequence changes. Nonconservative amino acid substitutions
are more likely to be signiﬁcant in terms of CTL recognition.
Despite the high degree of variability of p17
Gag, this protein
nonetheless contained a high frequency of immunodominant
Gag epitopes in the B-clade-infected persons. Thus, the differ-
ences observed in epitopes targeted by infected Africans and
infected Caucasoids do not appear to have been the result of
an artifact due, for example, to greater conservation of p24
Gag
in C-clade-infected persons. Clearly, the ideal approach, but an
impractical one, to determining the CTL activity of each HIV-
infected subject would be to determine the autologous virus
sequence beforehand. The best practical approach continues
to be screening for CTL responses using peptides based on the
most likely appropriate clade of infecting virus.
Understanding the role of CTL in pediatric infection has
been a particularly neglected area of investigation. The largest
previous epitope-speciﬁc study of infected children described
no more than three children (66). The data described here
show that in the 36 children studied (mean age, 7.5 years),
similar Gag epitopes are targeted in both infected children and
adults. Earlier studies of infected children have shown that,
particularly in subjects’ ﬁrst year of life, CTL responses are
hard to detect in comparison with those of adults at a similar
stage of infection (42, 43, 50). These low levels of CTL re-
sponses early in pediatric infection are seen in association with
a failure to control viremia in the ﬁrst 2 to 3 years of life (44,
55), in contrast to the rapid control of viremia observed in
association with the early appearance of CTL in adult HIV
infection and in SIV infection (7, 30, 40, 45, 53, 68). Further
studies in children younger than those described in this work
are therefore needed to better deﬁne the role of HIV-speciﬁc
CTL in controlling pediatric infection.
In conclusion, Gag-speciﬁc CTL responses in B- and C-
clade-infected African and Caucasoid children and adults are
focused on a small number of highly immunogenic regions.
The immunogenicity of these regions is partly explained by the
clustering together of similar or identical epitopes, but gener-
ally reﬂects the predominance of HLA-A2- and -A3-restricted
p17
Gag-speciﬁc responses in Caucasoids and HLA-B42- and
-B81-restricted p24
Gag-speciﬁc responses in Africans. Compar-
ison of epitope-speciﬁc responses in infected adults and chil-
dren shows that high-level CTL responses targeting the same
immunogenic regions were observed in children and adults.
These data also support the value of polyepitope vaccine de-
sign, since the theoretical obstacle posed by the degree of
MHC diversity is largely overcome by the tight clustering of
dominant epitopes which is observed. It will also be important
to deﬁne the immunodominant epitopes within the other ma-
jor immunogenic proteins (10), Nef, reverse transcriptase, and
envelope; to determine the effectiveness of CTL of these dif-
ferent speciﬁcities; and to further address the potential impor-
tance of clade-speciﬁc CTL activity in controlling HIV. Al-
though potential vaccine constructs might ideally match the
clade of virus to which vaccinees are likely to be exposed, the
cross-clade conservation of the region showing the highest
immunogenicity of the Gag peptides tested in these studies
(SG20) (p24
Gag residues 41 to 60) suggests that B-clade-based
5688 GOULDER ET AL. J. VIROL.vaccines would also be effective to a degree in African popu-
lations exposed to C-clade virus.
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